NCT00253201View on ClinicalTrials.gov

A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

PHASE3CompletedINTERVENTIONAL

Enrollment

636

Participants

Timeline

Start Date

Not specified

Study Completion Date

October 31, 1997

Conditions

Alzheimer DiseaseDementia

Interventions

DRUG

galantamine hydrobromide

All Listed Sponsors

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY